PDGFRB and chordoma: Following the immunohistochemical demonstration that PDGFR is activated in a majority of chordomas, patients with chordoma were treated with imatinib mesylate, a tyrosine kinase inhibitor active against PDGFR, BCR-ABL, and KIT [12, 13].